Latest news with #Qure.ai
Time of India
23-05-2025
- Health
- Time of India
Qure.ai launches AI tool to aid health workers in LMICs
Mumbai: AI solution provider company has introduced AIRA, an AI-powered co-pilot tool for frontline healthcare workers in low- and middle-income countries (LMICs) at the 78th World Health Assembly in Geneva this week. The company states that community health workers spend over 40 per cent of their time on manual data collection, yet many countries still lack sufficient population-level data for decision-making. According to the company, AIRA is designed to ease the burden on healthcare workers by automating symptom and patient history collection, supporting adherence to clinical protocols, and generating population-level health insights . It aims to address key challenges in LMICs, including a projected shortage of 11 million health workers by 2030 and the 17 million preventable deaths that occur annually. 'With AI, we can multiply every dollar spent and realize significantly more impact and returns in LMIC health systems,' said Prashant Warier, CEO and Founder,
The Print
10-05-2025
- Health
- The Print
Johnson & Johnson Medtech Partners with Qure.ai to Boost Early Detection of Lung Cancer in India
Mumbai (Maharashtra) [India], May 9: Johnson & Johnson MedTech, a global leader in surgical technologies and solutions, has onboarded a global leader in artificial intelligence (AI) for healthcare, as a strategic partner with Johnson & Johnson Private Limited, a Johnson & Johnson company, to enhance early detection of lung cancer in India. This collaboration brings together cutting-edge AI and medical technology, helping identify lung cancer at its most treatable stage. This initiative is part of Project BreatheEZ, a broader strategic collaboration between and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimizing early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, AI technology will be deployed across 10 hub medical centers in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu. In India, one in nine persons is likely to be diagnosed with cancer in their lifetime. It is an increasing health concern, and the projected cancer burden is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in 2021 to 29.8 million in 2025¹. This growing health challenge needs innovative solutions to improve early detection and ultimately save lives. Traditional diagnostic methods often fail to detect lung cancer at an early stage, leading to delays in treatment. Thus, this collaboration between Johnson & Johnson MedTech and marks a significant leap forward. By harnessing of artificial intelligence in the modalities of X-Ray & CT scans, Johnson & Johnson MedTech India & are enabling the detection of potential lung nodules that might otherwise be missed. This happens through flagging risky nodules in X-Rays and CT Scans that can potentially turn out to be malignant. It also introduces the concept of structured IPN clinics where there is a proactive impetus towards incidental screening of early-stage lung cancer. This partnership embodies Johnson & Johnson MedTech's commitment to enhancing early lung cancer detection, ultimately transforming the standard of lung cancer care. Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, 'Lung cancer continues to be one of the leading causes of cancer in both men and women. In India, where access to advanced healthcare facilities is often limited, especially in tier-2 and tier-3 cities, patients face significant challenges in receiving timely and effective diagnosis, which further delays access to treatment. Our collaboration with is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.' Reference: 1. ICMR and NCDIR World Cancer Day 2024, Close the care gap- Addressing cancer care in India, 04th – February – 2024 Surgical Solutions from Johnson & Johnson MedTech Across Johnson & Johnson, we are tackling the world's most complex and pervasive health challenges. For over 100 years, we have helped advance surgical care through our innovative portfolio across wound closure, adjunctive hemostats, surgical stapling and instruments, robotics and digital solutions. Together, with clinicians and healthcare experts around the world we are progressing what's next in surgery to better solve patient needs in metabolic and cardiovascular disease, cancer, and aesthetics and reconstruction. For more, visit (ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same) This story is auto-generated from a syndicated feed. ThePrint holds no responsibility for its content.
Time of India
08-05-2025
- Health
- Time of India
J&J Medtech, Qure.ai partner to boost early detection of lung cancer in India
Mumbai: Johnson & Johnson MedTech announced its collaboration with as a strategic partner with Johnson & Johnson Private Limited, to enhance early detection of lung cancer in India to bring together cutting-edge AI and medical technology which will help identify lung cancer at its most treatable stage. This initiative is part of Project BreatheEZ , a broader strategic collaboration between and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimizing early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, AI technology will be deployed across 10 hub medical centers in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu, stated the press release. In India, one in nine persons is likely to be diagnosed with cancer in their lifetime. It is an increasing health concern, and the projected cancer burden is expected to rise from 26.7 million DALYs (Disability-Adjusted Life Years) in 2021 to 29.8 million in 20251. This growing health challenge needs innovative solutions to improve early detection and ultimately save lives. Anuj Virmani, Managing Director, India, Johnson & Johnson MedTech, said, 'Our collaboration with is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.'
India Today
01-05-2025
- Health
- India Today
AI spots lung cancer signs in 5 million people, enables early diagnosis
A new technology screened chest X-rays of 5 million people across 20 countries and successfully detected early signs of lung cancer using artificial AI algorithm, developed through a collaboration between AstraZeneca and Indian health-tech company analyed scans conducted in Asia, the Middle East, Africa, and Latin America - regions where access to advanced diagnostic tools is often a global biopharmaceutical company headquartered in the UK, is known for developing life-saving treatments in oncology, cardiovascular, and respiratory diseases. It partnered with to deploy AI tools in resource-constrained settings, making early cancer detection more accessible. The screening program used proprietary algorithm, qXR, which analysed chest X-rays to identify abnormalities, particularly high-risk lung nodules that could indicate early-stage AI then flagged these cases for follow-up diagnostic tests like CT scans. So far, nearly 50,000 people with suspected nodules have been referred for further testing, enabling earlier diagnosis and faster intervention."Reaching the five million scan milestone demonstrates the power of digital innovation in transforming cancer care. AI-enabled tools like qXR are proving to be a cost-effective way to screen for lung cancer where radiologists or advanced imaging facilities may not be readily available," said Ti Hwei How, Vice President of International Oncology at CEO Prashant Warier noted that this collaboration has helped scale their AI technology in real-world clinical environments. "This milestone shows how AI can bridge the gap in healthcare access and strengthen systems through faster diagnosis," he cancer remains the leading cause of cancer-related deaths worldwide, particularly in low- and middle-income countries. In these regions, where screening programs are often lacking, technology like qXR offers a promising way forward.A recent study presented at the European Lung Cancer Congress 2025 found that qXR successfully identified high-risk nodules in 54.1% of cases, highlighting its utility as a frontline screening this, AstraZeneca and are now working with local governments and health agencies to expand the reach of AI-powered screening and bring timely lung cancer diagnosis to even more underserved Watch
Time of India
01-05-2025
- Health
- Time of India
AstraZeneca's AI lung cancer screening program executes 5 mn tests, flags 50k individuals at high risk
New Delhi: UK pharma major AstraZeneca in partnership with health-tech company , announced the completion of 5 million artificial intelligence (AI) enabled chest X-rays (CXRs) across more than 20 countries in Asia, the Middle East, Africa, and Latin America. The screen program is part of the World Economic Forum 's EDISON alliance 1 Billion Lives Challenge and under its commitment AstraZeneca's aims to demonstrate the potential of AI in improving lung cancer detection , especially in resource-limited healthcare settings. Of the 5 million excluded by the partners the CXRs revealed important findings, including lung nodules at high risk for cancer in nearly 50,000 people who were later referred for further testing and possible diagnosis. 'With successful implementation in countries such as Colombia, El Salvador and India, we are setting the stage for scaling this approach. We are actively partnering with Ministries of Health and policymakers to prioritise lung health and lung cancer on national agendas, including through AI-enabled screening programs to make a real difference,' said Ti Hwei How, Vice President, International Oncology, AstraZeneca. In 2020, under the Network initiative, AstraZeneca partnered with to harness qXR® technology for assessing CXRs and determining potential lung cancer risk. As per the drug maker by using AI to analyse routine X-rays for risks of cancer, healthcare professionals can focus further assessment, such as a low-dose CT scan to confirm or rule out lung cancer and is especially helpful in countries where resources are limited, as it helps to make the best use of available equipment and expertise, ensuring that those at highest risk get the attention they need and that screening programs are as effective as possible.
